Evidence map›Paper›PMID 29466367›Full record

ArticlePloS one2018

Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions.

Hideaki Nakamura, Hidemasa Bono, Keiko Hiyama, Takeshi Kawamoto, Yukio Kato, Takeshi Nakanishi, Masahiko Nishiyama, Eiso Hiyama, Nobuyuki Hirohashi, Eisaburo Sueoka and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Hideaki NakamuraDepartment of Radiation Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Hidemasa BonoDatabase Center for Life Science, Joint Support-Center for Data Science Research, Research Organization of Information and Systems, Mishima, Japan.
Keiko HiyamaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
Takeshi KawamotoDepartment of Dental and Medical Biochemistry, Hiroshima University, Hiroshima, Japan.
Yukio KatoDepartment of Dental and Medical Biochemistry, Hiroshima University, Hiroshima, Japan.
Takeshi NakanishiNippon Kayaku Co., Ltd., Tokyo, Japan.
Masahiko NishiyamaDepartment of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Eiso HiyamaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
Nobuyuki HirohashiDepartment of Radiation Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Eisaburo SueokaDepartment of Laboratory Medicine, Saga University Hospital, Saga, Japan.
Lorenz PoellingerCell and Molecular Biology, Medical Nobel Institute, Karolinska Institutet, Stockholm, Sweden.
Keiji TanimotoDepartment of Radiation Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.ORCID 0000-0003-4912-4197
Hiroshima University · JPHiroshima University Hospital · JPGunma University · JPKarolinska Institutet · SENippon Kayaku (Japan) · JPResearch Organization of Information and Systems · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor hypoxia contributes to a biologically aggressive phenotype and therapeutic resistance. Recent studies have revealed that hypoxia reduces expression of several DNA damage recognition and repair (DRR) genes via both hypoxia-inducible factor (HIF)-independent and -dependent pathways, and this induced genomic instability in cancer cells. We show here that one of the HIF-target genes-differentiated embryo chondrocyte (DEC)-plays a role in DNA damage response via transcriptional repression. Comprehensive gene expression and database analyses have revealed systemic repression of DNA-DRR genes in cancer and non-cancer cells under hypoxic conditions. Hypoxic repression in typical cases was confirmed by quantitative RT-PCR and promoter reporter experiments, and knockdown experiments indicated the critical role of DEC2 in such repression. Assessment of histone H2AX phosphorylation revealed that recognition and repair of DNA double-strand breaks (DSBs) induced by bleomycin or γ-ray irradiation were attenuated; moreover, Cleaved Caspase-3 levels were decreased with pre-conditioning under hypoxia: opposing phenomena were ascertained by knockdown of DEC2. Finally, pre-conditioning under hypoxia decreased the sensitivity of cancer cells to DSBs, and knockdown of DEC2 increased γ-ray sensitivity. These data imply that a critical reduction of DNA-DRR occurs via DEC-dependent transcriptional repression and suggest that DEC is a potential molecular target for anti-cancer strategies.

Indexed as

Cell HypoxiaDNA DamageGene Expression RegulationTranscription, GeneticBleomycinCartilageCell Line, TumorChondrocytesDown-RegulationGamma RaysHumansPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionBleomycin

Identifiers

PMID29466367
PMCPMC5821451
OpenAlexW2794011321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.